Promentis Pharmaceuticals, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Promentis Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2019).
SEC Form D · Dec 2019
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2019
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
No investor of Promentis Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Chad Beyer | Executive officer | Dec 2019 |
| Daniel Lawton | Executive officer | Dec 2019 |
| Klaus Veitinger | Executive officer | Sep 2017 |
| Tom Beck | Executive officer | Sep 2017 |
| Daniel Lawton | Director | Dec 2019 |
| Klaus Veitinger | Director | Dec 2019 |
| Patrick Schwarz-Schuette | Director | Dec 2019 |
| Stacey Seltzer | Director | Dec 2019 |
| Steve Squinto | Director | Dec 2019 |
| Thomas Beck | Director | Dec 2019 |
| Tom Beck | Director | Sep 2017 |
| David A Baker, PhD | Director | Aug 2009 |
| Ed Barthell | Director | Aug 2009 |
About
Company in Milwaukee, United States.